Background: Over the last ten years, a new class of drugs, known as the direct-acting oral
anticoagulants (DOACs), have emerged at the forefront of anticoagulation therapy. Like the …

Introduction: Dabigatran, a direct thrombin inhibitor, is 80% renally eliminated and
demonstrates multi-compartmental pharmacokinetics. Idarucizumab is a monoclonal …

BACKGROUND Real-life experience with idarucizumab, which reverses the anticoagulant
effect of dabigatran, is currently limited. OBJECTIVE To evaluate efficacy and safety of the …

BACKGROUND: Incomplete reversal with a recommended 5-g dose of idarucizumab has
been reported in patients with excessively high dabigatran concentrations. A timely …

Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor
Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis - PMC Back to Top Skip …

Introduction: Idarucizumab is a specific antagonist for dabigatran etexilate (DE). The recent
market authorization of idarucizumab in Europe and the USA may reassure prescribers of …

In patients with acute intracerebral hemorrhage (ICH), one of the major concerns is ongoing
bleeding or ICH expansion. Anticoagulated patients are at higher risk of ongoing expansion …

This retrospective audit reviews patients on dabigatran presenting with bleeding or requiring
urgent surgery in the Wellington region, whether they received idarucizumab appropriately …

The direct oral anticoagulants (DOAC)–dabigatran, rivaroxaban, apixaban and edoxaban–
were approved without the need for routine monitoring. However, in parallel with …

Dear Editor, Dabigatran is a direct thrombin inhibitor approved for oral anticoagulation. It is
primarily eliminated via the kidney. Renal dysfunction leads to a rise in plasma dabigatran …